HC Wainwright Raises Sanara MedTech (NASDAQ:SMTI) Price Target to $53.00

Sanara MedTech (NASDAQ:SMTI) had its price objective boosted by investment analysts at HC Wainwright from $51.00 to $53.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 68.25% from the company’s current price. HC Wainwright also issued estimates for Sanara MedTech’s FY2026 earnings at ($1.13) EPS.

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $46.00 price target on shares of Sanara MedTech in a research report on Wednesday, March 26th.

Sanara MedTech Trading Up 2.0%

NASDAQ:SMTI opened at $31.50 on Thursday. The stock has a fifty day moving average price of $31.06 and a two-hundred day moving average price of $33.45. The stock has a market capitalization of $279.97 million, a price-to-earnings ratio of -31.82 and a beta of 1.38. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.02 and a current ratio of 2.23. Sanara MedTech has a 1 year low of $25.86 and a 1 year high of $39.08.

Sanara MedTech (NASDAQ:SMTI) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.10). The business had revenue of $23.43 million during the quarter, compared to analysts’ expectations of $23.48 million. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%. As a group, sell-side analysts anticipate that Sanara MedTech will post -1.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SMTI. GAMMA Investing LLC boosted its stake in shares of Sanara MedTech by 8,423.8% during the first quarter. GAMMA Investing LLC now owns 1,790 shares of the company’s stock valued at $58,000 after acquiring an additional 1,769 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Sanara MedTech by 53.9% during the fourth quarter. Wells Fargo & Company MN now owns 1,893 shares of the company’s stock valued at $63,000 after acquiring an additional 663 shares during the last quarter. MetLife Investment Management LLC acquired a new stake in shares of Sanara MedTech during the first quarter valued at $82,000. BNP Paribas Financial Markets acquired a new stake in shares of Sanara MedTech during the fourth quarter valued at $106,000. Finally, Rhumbline Advisers boosted its stake in shares of Sanara MedTech by 14.9% during the first quarter. Rhumbline Advisers now owns 3,714 shares of the company’s stock valued at $115,000 after acquiring an additional 483 shares during the last quarter. Hedge funds and other institutional investors own 8.10% of the company’s stock.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.